A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Table of Contents PART I Avalo Therapeutics, Inc. (the “Company”, “Avalo” or “we”) is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β monoclonal antibody (“mAb”), targeting inflammatory diseases. Avalo was incorporated in Delaware and commenced operation in 2011, and completed its initial public offering in October 2015. Our Strategy Our strategy for increasing stockholder value includes: •Advancing our pipeline through development to regulatory approval.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 1.9M | 18M | - | - |
| Net Income | -100M | -35M | - | - | -84M | -64M |
| EPS | $-3.75 | $-20.91 | $-113.58 | $-255,120.00 | $-28,656.00 | $-12,441.60 |
| Free Cash Flow | 0 | -49M | -31M | -27M | -71M | -41M |
| ROIC | -42.0% | -50.1% | - | - | -150.9% | -131.5% |
| Gross Margin | - | - | 33.3% | 81.0% | - | - |
| Debt/Equity | 0.00 | 0.13 | 0.00 | -2.32 | 1.42 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -66M | -69M | -27M | -37M | -82M | -73M |
| Operating Margin | 0.0% | - | -1421.6% | -207.4% | - | - |
| ROE | -109.1% | -50.1% | - | - | -365.5% | -258.5% |
| Shares Outstanding | 18M | 11M | 11M | 0M | 0M | 0M |
Avalo Therapeutics, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 57.1%.
Avalo Therapeutics, Inc. (AVTX) has a 5-year average return on invested capital (ROIC) of -110.8%. This is below average and may indicate limited pricing power.
Avalo Therapeutics, Inc. (AVTX) has a market capitalization of $252M. It is classified as a small-cap stock.
Avalo Therapeutics, Inc. (AVTX) does not currently pay a regular dividend.
Avalo Therapeutics, Inc. (AVTX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Avalo Therapeutics, Inc. (AVTX) generated $-49 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Avalo Therapeutics, Inc. (AVTX) has a debt-to-equity ratio of 0.13. This indicates a conservatively financed balance sheet.
Avalo Therapeutics, Inc. (AVTX) reported earnings per share (EPS) of $-20.91 in its most recent fiscal year.
Avalo Therapeutics, Inc. (AVTX) has a return on equity (ROE) of -50.1%. A negative ROE may indicate losses or negative equity.
Avalo Therapeutics, Inc. (AVTX) has a 5-year average gross margin of 57.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 11 years of financial data for Avalo Therapeutics, Inc. (AVTX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Avalo Therapeutics, Inc. (AVTX) has a book value per share of $12.47, based on its most recent annual SEC filing.